At the "Pitch Night 2023", the company XO Life from the Digital Chemistry & Digital Health Hub Mannheim/Ludwigshafen presented its real-world platform for the healthcare and pharmaceutical industry. This platform aims to provide patients with better information about their illnesses and digital support in the use of medication and the implementation of therapies1. On the XO Life homepage, the ImpactMonitorᵀᴹ platform is presented as an entity that connects pharmaceutical companies and experts with their patients to provide first-class digital treatment support. It promises better informed, more loyal and empowered patients with better treatment outcomes. The ImpactMonitorᵀᴹ platform is described as a globally unique one-stop solution that provides all types of product and treatment support. It covers more than 200,000 medicines and 30,000 conditions in Europe and aims to provide efficient digital support for patients and users without the need for a separate app for each medicine and condition.
Within the ImpactMonitorᵀᴹ platform, there is a special area called MedWatcherᵀᴹ where leading research institutes are active. On MedWatcherᵀᴹ, pharmaceutical and medical technology companies can obtain their own product and treatment rooms. The platform makes it possible to publish educational content about diseases and treatments and to easily offer digital product or treatment companions for the entire product portfolio. In addition, high-quality standardized and specific patient reports on diseases, treatments and products can be obtained through the platform. The collection, processing and tracking of patient adverse drug reaction reports will also be digitized, enabling better health monitoring.
